Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

Rasna Therapeutics, Inc. Appoints Dr Alessandro Padova as Chairman

Rasna Therapeutics
Posted on: 18 Oct 16

Rasna Therapeutics, Inc. (OTCQB: RASP), a development stage biotechnology company focused on the development of cancer drugs, today announced the appointment of Dr Alessandro Padova as Chairman with immediate effect.

“We are delighted to welcome Alessandro to the Rasna team and look forward to the positive contribution of his leadership, experience and successful international track record of progressing assets through clinical development,” commented Jim Tripp, CEO of Rasna.

Dr Padova will continue to serve in his role as Chief Executive Officer of Ri.MED Foundation, a unique US-Italy public-private translational research enterprise. He has previously held senior executive, managerial and scientific roles in the pharmaceutical and biotechnology sector with several prestigious UK and Italian biotech companies including Peptide Therapeutics, Medivir UK, Astex Technology, C4T, Siena Biotech and IRBM Science Park, where he led and implemented business, management and R&D strategies.

Dr Padova obtained a BSc in Chemistry from the University of Kent and a PhD in Synthetic Organic Chemistry in 1994 at Exeter University, followed by an industrial post-doctoral fellowship at Parke-Davis Neuroscience Research Centre in Cambridge, UK.


About Rasna Therapeutics, Inc.

Rasna Therapeutics, Inc. is a development stage biotechnology company focused primarily on the development of drug candidates for leukemia and lymphoma. Abnormal epigenetic modification is recognized to play an important role in the pathogenesis of acute myeloid leukemia (AML), leading to silencing of genes involved in tumor suppression and cellular reproduction. Rasna’s focus on inhibition of lysine specific demethylase-1 (LSD1), an enzyme involved in epigenetic control, represents a promising and novel approach towards AML. Rasna has developed novel irreversible and reversible LSD1 regulators that have shown appropriate effects on the LSD1 gene in-vitro and in IND-enabling pre-clinical studies.

Rasna Therapeutics Forward-Looking Statements

This press release contains “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995, regarding the research, development and commercialization of pharmaceutical products. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Forward-looking statements in the press release should be evaluated together with the many uncertainties that affect Rasna Therapeutics’ business and Rasna Therapeutics undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

View source version on

Business Wire

Last updated on: 18/10/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.